- Report
- February 2025
- 125 Pages
Global
From €2200EUR$2,490USD£1,927GBP
- Report
- April 2025
- 200 Pages
Global
From €3966EUR$4,490USD£3,475GBP
- Report
- February 2025
- 200 Pages
United States
From €5256EUR$5,950USD£4,605GBP
- Report
- November 2024
- 120 Pages
Global
From €5256EUR$5,950USD£4,605GBP
- Report
- January 2023
- 470 Pages
Global
From €4417EUR$5,000USD£3,870GBP
- Report
- August 2023
- 145 Pages
Global
From €2783EUR$3,150USD£2,438GBP
- Report
- March 2024
- 303 Pages
Global
From €5618EUR$6,360USD£4,923GBP
€7023EUR$7,950USD£6,153GBP
- Report
- September 2022
- 392 Pages
Global
From €3180EUR$3,600USD£2,786GBP
- Report
- September 2022
- 144 Pages
Middle East, Africa
From €1325EUR$1,500USD£1,161GBP
Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease. It is the first and only FDA-approved prescription eye drop that contains a combination of two active ingredients, lifitegrast and sodium hyaluronate. Xiidra works by reducing inflammation in the eyes, which can help reduce the signs and symptoms of dry eye disease. It is available in both single-use and multi-dose vials.
Xiidra is a relatively new entrant to the optical disorders drugs market, but it has quickly become a popular treatment option for dry eye disease. It is generally well-tolerated and has been shown to be effective in reducing the signs and symptoms of dry eye disease.
Companies in the Xiidra market include Shire, Novartis, Allergan, and Bausch + Lomb. Show Less Read more